Q&A on the Johnson & Johnson COVID-19 vaccine with Mona Chitre, PharmD, Chief Pharmacy Officer and Vice President of Clinical Strategy and Innovation at Excellus BlueCross BlueShield

Posted on March 9, 2021

Dr. Chitre leads Excellus BlueCross BlueShield’s pharmacy strategy and is responsible for driving affordability, innovation and operational excellence. She completed her undergraduate and graduate training at Rutgers University and her post-doctoral primary care residency at the Buffalo VA Medical Center in Buffalo, New York.

Q: Dr. Chitre, the Johnson & Johnson (J&J) vaccine is the third COVID-19 vaccine being distributed in the U.S. Is it safe? Why do we need a third vaccine option?
A: All vaccines have the same goal – to protect us. The J&J vaccine was tested thousands of times to ensure safety and is authorized for use in the U.S. It’s important that everyone who wants the COVID-19 vaccine can receive it. In addition to the Moderna and Pfizer-BioNTech vaccines, the J&J vaccine is another way to help increase protection against the virus that causes COVID-19. Since all three vaccines are safe, the best vaccine is the one you have access to.

Q: How does the J&J vaccine differ from Moderna’s and Pfizer-BioNTech’s?
A: The J&J vaccine is a single dose which offers maximum protection quicker than Moderna’s and Pfizer-BioNTech’s vaccines. The J&J vaccine has proven to be 66% effective at preventing moderate to severe cases of COVID-19. With all three vaccine options, no fragment of the live virus is in the vaccine so the vaccine itself cannot make you sick with COVID-19.

Q: Should we be concerned with a less effective rate?
A: No, there is no need to be concerned. The only way to accurately compare the effectiveness of these vaccines is by direct comparison in head-to-head clinical trials, which did not happen across the three vaccine options. Testing took place in different regions, at different points in time, and with varying COVID-19 occurrences. It is best not to compare the effective rates between the vaccines.

The data proves that the J&J vaccine is 85% effective against severe COVID-19 cases, and 100% effective at preventing death from COVID-19. Based on the data, the J&J vaccine is a very safe and effective option.

Q: There is mention of a booster vaccine to help protect against the COVID-19 variants. What information is known or suggested about this?

A: Scientists are currently looking into if a booster dose is needed to address variants. It is emerging science at this time, but it is still recommended that you get your vaccine as soon as it is available for you.

Q: We know that vaccines were given to high-risk groups first. The data suggests that the number of deaths in nursing homes is going down by more than 60%. Do you feel this is because of the vaccine?
A: Absolutely. Nursing home residents were among the first people to receive the vaccine. The data shows how powerful the vaccines are against the virus, which is encouraging to hear. Reports like these make me so hopeful as the vaccines continue to rollout. I’m excited for my children to be reunited with their grandparents. I’m optimistic about the future.

Other Network News

logo
November 18, 2026

ARCO Helps SupplyOne Evaluate Facility Needs for National Expansion

The project supports SupplyOne’s continued growth by consolidating key warehouse, office, and production functions into a manufacturing environment designed around the company’s operational needs.

Christopher Andreucci
November 18, 2026

Member News: Harris Beach Murtha Names New CEO

Harris Beach Murtha Names Christopher A. Andreucci New CEO

Cornell Cooperative Extension Tree Syrup Workshop
November 16, 2026

Cornell Cooperative Extension Tree Syrup Workshop

This program will provide an overview of the different types of trees that can be tapped for syrup.

Alex Levi portrait photo
November 13, 2026

Lifetime Benefit Solutions Names Alex Levi President

Lifetime Benefit Solutions (LBS) has named Alex Levi president, effective Oct. 3, 2026.

The Lodge at Turning Stone Honored with Prestigious 2027 Condé Nast Johansens Award for ExcellenceThe Lodge at Turning Stone’s exceptional standard for hospitality, fine dining and restorative wellness spotlighted in the recognition
November 12, 2026

The Lodge at Turning Stone Honored with Prestigious 2027 Condé Nast Johansens Award for Excellence

The Lodge at Turning Stone’s exceptional standard for hospitality, fine dining and restorative wellness spotlighted in the recognition.

Oswego YMCA's 35th Annual Reindeer Run 5K Run/WalkDash into the holiday spirit! Join us for the Oswego YMCA’s 35th Annual Reindeer Run 5K Run/Walk on Saturday, December 5 at 9:30am!
November 6, 2026

Oswego YMCA's 35th Annual Reindeer Run 5K Run/Walk

All ages and abilities are welcome to enjoy this festive community tradition filled with fitness, fun and holiday cheer!

November 5, 2026

Harris Beach Murtha Recognized in 2027 Edition of Best Law Firms

Best Lawyers® has released the 2027 Best Law Firms rankings in which Harris Beach Murtha was recognized nationally and regionally.

November 5, 2026

Seminar: Your Product Is Great. Too Bad Nobody Will Pay for It.

The speaker will discuss the process and timing of product reimbursement during a startup’s strategic planning and the importance of implementing a reimbursement plan.

Tenbit Emiru
November 4, 2026

Excellus BlueCross BlueShield Names Dr. Tenbit Emiru Chief Medical Officer

Tenbit Emiru, MD, PhD, MBA has joined Excellus BCBS and its parent company, The Lifetime Healthcare Companies, as enterprise chief medical officer and senior vice president of medical services.